Skip to content

Robin Shane Readnour, Director at AN2 Therapeutics, sold ANTX on Sep 9, 2026

Data as of Oct 16

▼ SELL$3.5K585 shares at $6.02Robin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.
Watch ANTX
Traded
Sep 9, 2026
Disclosed
Sep 11, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Robin Shane Readnour, Director at AN2 Therapeutics, sold ANTX on Sep 9, 2026TRADEDDISCLOSED
ANTXSimilar stocks (XLV — its sector index fund), rebased to ANTX's price on the disclosure day
ANTX since disclosure
−37.5%
after the sale
Similar stocks (XLV) since disclosure
+6.9%
XLV — its sector index fund

Change in closing price from Sep 11, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLRobin Shane Readnour DirectorANTX AN2 Therapeutics, Inc.$3.2Kdisclosed Sep 11 · filed 2 days after the trade

See every trade on ANTX →